Slide 1: Semperit Group Q1 2022 Investor Presentation
SEMPERIT GROUP Q1 2022 INVESTOR PRESENTATION Karl Haider, CEO Petra Preining, CFO 18 May 2022 1
Slide 2: Agenda
Agenda Key Highlights (p.2) Operational Performance (p.4) Financial Performance & Strategy (p.11) Outlook (p.21) Appendix (p.24) 2 Investor Presentation Q1 2022 I 18 May 2022 I Investor Relations
Slide 3: Q1 2022 Highlights
Q1 2022 Highlights Strong Q1’22 results against exogenous economic shocks; resilience in Industrial and normalisation of special cycle in Medical Sector Industrial Sector: strong order book and sales; headwinds from input prices – close collaboration of supply chain management, procurement, R&D and
Slide 4: Agenda
Agenda Key Highlights (p.2) Operational Performance (p.4) Financial Performance & Strategy (p.11) Outlook (p.21) Appendix (p.24) 4 Investor Presentation Q1 2022 I 18 May 2022 I Investor Relations
Slide 5: Industrial Sector more resilient with continuing top-line growth
Industrial Sector more resilient with continuing top-line growth Revenues in EUR m Quarterly development of EBITDA (in EURm) and EBITDA margin (in%) Q1’19 –Q1’22 since 2019 +20.9% +31.4% 171.0 21.3 19.1 17.3 17.1 141.4 16.1 14.5 15.9 15.0 16.4 15.5 130.1 28.2 121.6 10.5 27.1 10.3 12.1 26.4 24.5 23.2
Slide 6: Semperflex Q1 2022
Semperflex Q1 2022 Continuing revenue growth and stronger margins 24.4% 27.2% 24.5% 24.5% 22.8% 19.9% 22.5% 23.3% EBITDA in € m 20.0% 19.3% 20.4% 18.1% 15.9% EBITDA margin Semperflex 19.6 13.9 14.5 14.0 11.4 12.3 13.9 11.2 13.9 10.8 8.7 9.3 7.2 Q1’19 Q2’19 Q3’19 Q4’19 Q1’20 Q2’20 Q3’20 Q4’20 Q1’21 Q
Slide 7: Sempertrans Q1 2022
Sempertrans Q1 2022 First visible signs of segment’s recovery reflected in results 14.2% 16.7% 15.4% 13.1% EBITDA in € m EBITDA margin Sempertrans 9.0% 7.6% 5.4 5.0 3.3% 3.7 4.6 5.4% 4.5% 1.3 2.5% 3.8% 1.6 2.1 0.0% 1.4% 1.4 0.8 1.0 0.8 1.0 1.3 0.0 0.4 1 2 Q1’19 Q2’19 Q3’19 Q4’19 Q1’20 Q2’20 Q3’20 Q4
Slide 8: Semperseal Q1 2022
Semperseal Q1 2022 Margins under pressure due to time lag in in passing on higher costs 14.1%13.2% 14.7% 14.7% 12.8% 12.0% 12.6% EBITDA in € m 9.8% 7.5% Semperseal 7.9% 6.5% EBITDA margin 3.9 3.0% 4.2 4.1 3.4 3.3 3.2 2.9 2.5 2.4 3.0% 2.4 1.7 0.6 0.9 Q1’19 Q2’19 Q3’19 Q4’19 Q1’20 Q2’20 Q3’20 Q4’20 Q1
Slide 9: Semperform Q1 2022
Semperform Q1 2022 Continuing top-line growth – but margin pressure due to cost inflation 22.6% 19.6% 18.4% 17.5% 19.6% 17.7% EBITDA in € m 12.2% 12.9% 15.4% 15.2% 14.1% Semperform 10.3% 12.2% EBITDA margin 4.8 5.0 4.0 4.1 3.5 4.0 3.6 2.7 3.1 3.3 3.2 2.5 2.5 Q1’19 Q2’19 Q3’19 Q4’19 Q1’20 Q2’20 Q3’20
Slide 10: Medical Sector / Sempermed segment Q1 2022
Medical Sector / Sempermed segment Q1 2022 Further price normalisation while still above pre-Corona level 57.7% 51.6% 54.6% 37.5% 45.9% EBITDA in € m EBITDA margin Sempermed 19.7% 105.3 115.3 21.7% 83.0 12.6% 0.8% 2.3% -0.1% 6.1% 44.4 56.9 -1.2% 18.2 23.7 13.3 -0.9 0.6 1.8 -0.1 4.8 1 Q1’19 Q2’19 Q3’
Slide 11: Agenda
Agenda Key Highlights (p.2) Operational Performance (p.4) Financial Performance & Strategy (p.11) Outlook (p.21) Appendix (p.24) 11 Investor Presentation Q1 2022 I 18 May 2022 I Investor Relations
Slide 12: Q1 2022 Financial Highlights
Q1 2022 Financial Highlights Robust industrial performance despite high inflation and supply constraints while normalisation of Covid-related special effects in Medical Sector Working capital management: proactive inventory build-up due to Russian war in Ukraine and continuing price increases Effici
Slide 13: Revenue development
Revenue development in € m -14% 7.9 6.4 25.1 1.4 323.1 277.0 -86.9 +31.4% -45.0% +45.9% +5.1% +27.5% +32.5% Industrial Sector Medical Sector Q1 2021 Semperflex Sempertrans Semperseal Semperform Sempermed Q1 2022 Revenue 79.8m 28.3m 36.6m 26.2m 106.1m Q1 2022 % change of each segment / sector refers
Slide 14: Resilient performance in Industrial offset by disproportionate decline in Medical
Resilient performance in Industrial offset by disproportionate decline in Medical in € m -70% 7.3 0.2 0.2 122.2 -1.8 0.3 36.5 -91.9 Q1 2021 Semperflex Sempertrans Semperseal Semperform Sempermed Corporate Q1 2022 EBITDA 122.2 12.3 1.0 4.2 3.1 105.3 -3.7 Q1 2021 EBITDA 19.6 1.3 2.4 3.2 13.3 -3.2 36.5
Slide 15: Major drivers of operating performance
Major drivers of operating performance -70% 122.2 Total Sales Effect: € -46.1m 14.6 -7.1 -60.7 -6.2 thereof: -10.5 Industry -6.3 36.5 Price Volume -5.9 € +36.5m € +4.4m -3.7 Medical Price Volume € -97.1m € +10.3m EBITDA Price Effect Volume Change in Cost of Energy Logistics Personnel Misc. EBITDA Sa
Slide 16: Overview of key financial KPIs, Q1 2019 – Q1 2022
Overview of key financial KPIs, Q1 2019 – Q1 2022 Q1 2019 Q1 2020 Q1 2021 Q1 2022 EBITDA, in € m 16.5 16.9 122.2 36.5 EBITDA margin, in % 7.7 8.5 37.8 13.2 EBIT, in € m 7.8 9.8 110.8 23.7 EBIT margin, in % 3.7 4.9 34.3 8.6 Earnings after tax, in € m 3.2 -1.7 85.5 15.5 Free Cashflow, in € m 18.6 23.3
Slide 17: Quarterly CAPEX development 2020-2022
Quarterly CAPEX development 2020-2022 • Tangible CAPEX increase through the cycle with post-Covid catch-up effect due to supply chain constraints • Outlook 2022: planned to be approximately at 2021 level • Industrial Sector: increasing focus on growth CAPEX CAPEX per segment in € m +68% 16.8 17.1 2.
Slide 18: Free cash flow development
Free cash flow development Decline in operating cash flow implies normalisation of Covid-related special effect in Medical Sector Operating cash flow impacted by proactive inventory build up Investment cash flow driven by increased CAPEX level 70 59 30 23 18 -11 0 -7 -18 -31 1 Q1’20 Q1’21 Q1’2
Slide 19: Working Capital overview
Working Capital overview Components of Working Capital in € m 21.4%1 17.5%1 17.0%1 16.1%1 19.6%1 222.2 225.4 204.7 209.5 190.3 173.1 203.1 Inventories 165.6 177.2 186.8 134.0 128.9 111.3 132.6 Trade receivables 98.8 -81.7 -89.8 -78.9 -95.3 -113.5 Trade payables 31 March 2021 30 June 2021 30 Sept 202
Slide 20: Balance sheet structure and financial profile
Balance sheet structure and financial profile Balance sheet structure Financial profile as of 31 March 2022 Balance sheet 31/03/2022: € 997m Balance sheet 31/12/2021: € 959m Cash and cash equivalents at € 231m Unused credit facilities total € 90m Non-current 407 407 Equity (incl. hybrid capital)
Slide 21: Agenda
Agenda Key Highlights (p.2) Operational Performance (p.4) Financial Performance & Strategy (p.13) Outlook (p.21) Appendix (p.24) 21 Investor Presentation Q1 2022 I 18 May 2022 I Investor Relations
Slide 22: Management Agenda and Expectations for 2022
Management Agenda and Expectations for 2022 Focus on Starting Protective glove prices Strict cost management strategic growth base line further declining from to maintain competitive of the in 2022 plateau in Q2’21 position Industrial Sector accelerated Additional supply Strong focus on Geopolitical
Slide 23: Contact and financial calendar
Contact and financial calendar Investor Relations Semperit Financial Calendar 2022 Judit Helenyi, Director Investor Relations 18.5.2022 Report on Q1 2022 17.8.2022 Half-year financial report 2022 +43 1 79777 - 310 www.semperitgroup.com/en/ir 16.11.2022 Report on Q1-3 2022 Am Belvedere 10 1100 Vienna
Slide 24: Agenda
Agenda Key Highlights (p.2) Operational Performance (p.4) Financial Performance & Strategy (p.13) Outlook (p.21) Appendix (p.24) 24 Investor Presentation Q1 2022 I 18 May 2022 I Investor Relations
Slide 25: Sectors and Group: Q1 2022 vs Q1 2021
Sectors and Group: Q1 2022 vs Q1 2021 1) 2) 3) Industrial Sector Medical Sector Semperit Group in EUR m Q1 2022 Q1 2021 % Q1 2022 Q1 2021 % Q1 2022 Q1 2021 % Revenue 171.0 130.1 +31.4% 106.1 192.9 -45.0% 277.0 323.1 -14.2% EBITDA 26.4 20.6 +28.1% 13.3 105.3 -87.3% 36.5 122.2 -70.1% EBITDA margin 15.
Slide 26: Semperit Group adj. where applicable
Semperit Group adj. where applicable Semperit Group adj. where applicable Q3 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q4 Q1 Q2 Q3 Q4 FY Q1 1) 2) 3) 2020 2020 2019 2019 2019 adj. 2019 adj. 2019 2020 2020 adj. 4) 2020 adj. 5) 2021 2021 2021 2021 2021 2022 in EUR m adj. adj. Revenue 212.9 224.4 214.9 188.3 840.6 199.1
Slide 27: Semperflex and Sempertrans (adj. where applicable)
Semperflex and Sempertrans (adj. where applicable) Semperflex (Hoses) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 2022 2019 2019 2019 2019 2019 2020 2020 2020 2020 2020 2021 2021 2021 2021 2021 in EUR m Revenue 61.1 59.7 53.8 48.0 222.7 46.8 51.5 46.6 45.0 189.9 54.7 59.7 57.7 68.4 240.5 79.8 EB
Slide 28: Semperform and Semperseal (adj. where applicable)
Semperform and Semperseal (adj. where applicable) Semperform (Window and door profiles, Handrails) - before 2020 FY Q1 Q2 Q3 FY Q1 Q2 Q3 Q4 FY 2017 2018 2018 2018 2018 2019 2019 2019 2019 2019 in EUR m adj. Revenue 185.0 47.5 50.7 50.3 192.2 49.9 50.5 47.8 42.4 190.6 EBITDA 21.5 4.5 7.3 6.2 21.9 7.9
Slide 29: Sempermed (adj. where applicable)
Sempermed (adj. where applicable) Sempermed (Gloves) Q3 Q2 Q3 FY Q1 Q2 Q4 FY Q1 Q4 Q1 Q2 Q3 Q4 FY 2019 2) 2020 2020 5) 2020 Q1 2022 2019 2019 1) 2019 2019 2020 3) 4) 2020 6) 2021 2021 2021 2021 2021 in EUR m adj. adj. adj. adj. Revenue 71.5 76.4 78.2 67.3 293.3 77.5 92.2 118.4 161.1 449.2 192.9 199.
Slide 30: Key figures 2011-2021
Key figures 2011-2021 Key performance figures 2016 2017 2018 2019 2020 in EUR m 20111) 2012 2013 2014 3) 20153) 2021 adj.4) adj.5) adj.6) adj.7) adj.8) Revenue 820.0 828.6 906.3 858.3 914.7 852.4 874.2 878.5 840.6 927.6 1,182.2 EBITDA 110.0 108.7 132.5 101.9 96.2 74.7 35.8 50.3 63.8 208.6 361.8 EBIT
Slide 31: Overview price indices Butadiene
Overview price indices Butadiene Price movements for raw materials1) became highly unpredictable Price indices Butadiene as main raw material for synthetic rubber / latex 250 Ø YTD ø 2019 ø 2020 2022 200 150 100 50 ø 2021 0 Butadiene Europe Butadiene Korea 1) Selected raw materials are shown for ill
Slide 32: Overview price indices LFO-F-NWE / wire rod
Overview price indices LFO-F-NWE / wire rod Significant increase for raw material1) used in industrial segments Price index LFO-F-NWE Price index wire rod 225 200 200 ø 2019 ø 2020 ø 2021 ø 2019 ø 2020 ø 2021 175 175 150 150 125 125 100 100 75 75 50 50 Ø YTD Ø YTD 2022 2022 25 25 Fuel Oil 1% Sulphur
Slide 33: Product / market position / segment overview, FY 2021
Product / market position / segment overview, FY 2021 in EUR m Semperit Group Industrial Sector Medical Sector Group Semperflex Sempertrans Semperform Semperseal Sempermed Revenue 1.182.2 240.5 / 20%1) 104.5 / 9%1) 90.6 / 8%1) 120.5 / 10%1) 626.1 / 53%1) EBITDA 361.82) 51.3 6.8 12.4 11.6 301.1 Emplo
Slide 34: Shareholder Structure
Shareholder Structure Shareholder structure Semperit is listed on the Vienna Stock Exchange since 1890 Total of 20,573,434 shares B & C Holding Österreich GmbH is part of < 46% B & C Privatstiftung, an Austrian based private foundation / trust > 54% Primary focus of B & C is pursuing the fou